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Aging per se is associated with decrements in skeletal 
muscle force, power and mass that can be attenuated but 
not completely prevented by exercise training. Female 
aging is characterized by menopausal hormonal change 
in middle-age, which is accompanied by acceleration in 
muscle decrements, partially attenuated by estrogen 
supplementation [1]. Despite the presence of well 
documented data demonstrating that muscle cells 
express both estrogen and androgen receptors enabling 
anabolic receptor-dependent signaling, the research 
focused mostly on male/androgen signaling pathways 
with less input resulting from female-specific aspects of 
aging. Amassing evidence implicates estrogens, in 
particular the biologically most active estradiol (E2) that 
is lost in menopause, to be also involved in the 
regulation of several aspects of mitochondrial function, 
including biogenesis, bioenergetics, mitochondrial 
fusion and fission processes, mtDNA transcription and 
apoptosis [2]. 
Despite intensive research efforts following the finding 
of the role of sex-difference in the pace of muscle aging 
[3], the molecular mechanisms explaining such 
difference are not yet fully understood. Omics 
approaches, covering the molecular picture and 
including investigations on RNA, proteome and meta-
bolome levels are desired to facilitate a comprehensive 
view of plethora of various responses to hormonal 
aging. To complement the previous research on the 
female muscle proteome [4, 5], our recent study focused 
on proteome level differences evoked by menopause-
associated hormonal differences. We utilized vastus 
lateralis muscle samples of premenopausal (30- to 34-
year-old) women in comparison with postmenopausal 
(54- to 62-year-old) monozygotic co-twin women 
whom the other sister had never been exposed to and 
the other was a current hormone therapy user (HRT) 
[6]. The HRT medications used by the study 
participants involved estrogen only, estrogen and pro-
gestogen or tibolone based HRT. 
Using explicitly developed sample preparation allowing 
for efficient solubilization of insoluble muscle proteins 
combined with label free tandem mass spectrometry 
(nano-LC-HD-MSE) and bioinformatics, we identified 
in total 1583 and quantified 797 muscle proteins. The 
quantified proteins were subjected to bioinformatic 
filtering (fold change above 1.5, P < 0.05,  quantified on  








≥ 2 unique peptides), to identify differentially expressed 
proteins (DEPs) amid postmenopausal and premeno-
pausal women. The non-users of HRT vs. premeno-
pausal women comparison yielded 21 DEPs specific to 
aging coupled with low systemic E2 levels. The 
comparison of HRT users vs. premenopausal women 
revealed 58 DEPs related to aging with E2-
supplementation while 93 proteins were shared among 
both conditions. Furthermore, to identify HRT-use-
associated DEPs at genetically controlled, same age 
background postmenopausal HRT users were compared 
to their non-using co-twins resulting in the identifica-
tion of 53 DEPs and 83 additional ones that were 
specific to the use of tibolone HRT. The two E2-
containing medication types were combined, while 
tibolone based HRT was investigated separately due to 
its known multiple effects including estrogenic, 
progestogenic and androgenic functions. The intra-pair 
differences in systemic hormones and in muscle 
performance characteristics did not differ among co-
twin pairs using two different types of E2-containing 
HRT. On the contrary, the intra-pair difference of 
systemic hormones and specific muscle force (knee-
extension force/muscle mass) were significantly 
different within co-twin pairs using tibolone than in co-
twin pairs using E2-HRT. 
Functional annotation of the DEPs was performed using 
Ingenuity Pathway Analysis software. In total, 39 
significantly affected canonical pathways were found in 
one or more comparisons. The contributing proteins 
formed three major functional clusters encompassing 
mitochondrial functions, cytoplasmic energy meta-
bolism, and cellular signaling, adding further insight to 
the accumulating evidence that E2 participates also in 
muscle in the regulation of metabolism and 
mitochondrial activities including bioenergetics and 
apoptosis [2].  
Based on the observed alterations in muscle protein 
levels, it appeared that E2 constituted a major upstream 
pathway regulator and pinpointed downstream func-
tions, cell death and glycolytic cascades, to be affected. 
This complemented the canonical pathway analyses 
identifying glycolysis/gluconeogenesis as well as 
oxidative phosphorylation/mitochondrial dysfunction to 
be influenced by aging and the use of HRT. Taken 
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regulator of muscle cellular function contributing to 
aging-associated decrement in muscle physiology and 



































Our results on estrogenic regulation of muscle signaling 
will stimulate in-depth investigations on mechanisms of 
hormonal aging and its consequences on muscle aging. 
Furthermore, our findings bring insights into the 
regulatory effects of estrogen and the potential of HRT 
to mitigate the degree of muscular aging. Moreover, the 
strategy of which type of HRT to prescribe for a woman 
who is seeking help to control menopausal symptoms is 
of clinical importance. By providing evidence, for the 
first time at the human proteome level, that E2 is a 
major regulator of different trajectories of the muscle 
energy pathways our study is relevant to aging women’s 
health and may likely be utilized in future interventions 
aiming at prevention or treatment of menopause-
associated metabolic dysregulation, linked to higher 
prevalence of the cardio-metabolic diseases among 
post-menopausal women [7]. 
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Figure  1.  Outline  of  proteomics  investigations  in  the
female  muscle.  Non‐HRT:  postmenopausal  non‐hormone
users, PRE: premenopausal women, E2‐based HRT: postmeno‐
pausal E2‐HRT users, Tib‐HRT‐ postmenopausal: Tibolon‐based
HRT  users,  FASP:  filter  assisted  sample  preparation,  IPA:
Ingenuity  Pathway  Analysis,  DEPs:  differentially  expressed
proteins. 
